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Abstract: Bariatric surgery is an effective treatment for achieving significant weight loss and improv-
ing metabolic comorbidities such as type 2 diabetes mellitus (T2DM). The aim of our study was to
investigate clinical factors related to T2DM remission in obese patients who had undergone bariatric
surgery. Methods: A cohort of patients with T2DM and a minimum of class II obesity undergoing
bariatric surgery had their clinical and anthropometric variables assessed. The statistical evaluation
included multivariate analyses of clinical factors predicting a T2DM remission two years post-surgery.
Results: 83 patients were included (mean age 44.13 ± 10.38 years). Two years post-surgery, the
percentage of excess weight lost was 63.43 ± 18.59%, and T2DM was resolved in 79.5% of the patients.
T2DM remission was directly related to a high body mass index (BMI) (OR: 1.886; p = 0.022) and the
absence of macro-vascular complications (OR: 34.667; p = 0.002), while it was inversely associated
with T2DM with a duration longer than 5 years (OR: 0.022; p = 0.040) and baseline insulin treatment
(OR: 0.001; p = 0.009). 15.6% of the patients presented early complications and 20.5% developed
late complications. Conclusion: In our study sample, bariatric surgery proved to be an effective
and safe technique for sustained medium-term weight loss and the resolution of T2DM. A higher
baseline BMI, a shorter T2DM duration, non-insulin treatment, and the absence of macro-vascular
complications are factors predictive of T2DM remission.
Keywords: type 2 diabetes mellitus; diabetes remission; metabolic surgery; bariatric surgery
1. Introduction
Type 2 diabetes mellitus (T2DM) is the metabolic comorbidity that is most associated
with obesity, such that morbid obesity (BMI ≥ 40 kg/m2) increases the risk of developing
T2DM tenfold. In patients with morbid obesity who have not yet developed T2DM,
excess body adiposity is associated (in more than 90% of the cases) with insulin resistance,
decreased adiponectin levels, atherogenic dyslipidemia, non-alcoholic steatohepatitis,
and the secretion of pro-inflammatory cytokines—all of which entail an increased risk of
acquiring cardiovascular diseases [1,2].
Bariatric surgery is the most effective therapy for reducing morbid obesity, both in
terms of immediate weight loss as well as the long-term maintenance of the weight lost and
the resolution of associated metabolic comorbidities. Bariatric surgery is usually reserved
for patients with BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2, but it is associated with other
comorbidities (such as diabetes, hypertension, and dyslipidemia) in which dietary and
pharmacological treatments have failed. In addition to their clinical status, the patients need
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to satisfy certain psychological conditions, which can influence the long-term outcomes of
the surgery [3,4].
In the 1990s, an increase in the number of bariatric interventions aimed at reducing the
BMI of patients with morbid obesity revealed that other associated comorbidities improved
as well. These included T2DM via mechanisms beyond the purely anatomical ones, which
were inherent in the surgical technique employed [5]. The concept of metabolic surgery
was introduced by Pories et al. [6] in 1995, and various studies have followed since then. In
2004, Buchwald et al. performed a meta-analysis of 22,094 patients with obesity and T2DM
who underwent different bariatric surgery procedures. The analysis indicated a 76.8%
overall resolution of T2DM. Particularly noteworthy was this percentage being greater in
techniques involving a malabsorption element (gastric bypass or biliopancreatic diversion)
as compared to procedures involving merely a restrictive element (sleeve gastroplasty or
adjustable gastric banding) [7]. Hence, some practitioners propose the use of bariatric
surgery as metabolic surgery in patients with T2DM and a BMI lower than the currently
accepted criteria [8].
Even though the therapeutic benefits of the different types of bariatric surgery in
T2DM are clear, the factors predictive of post-surgery diabetes resolution are not so clear;
data from the literature are not without controversy. We must also consider that these
procedures can be irreversible and are not free of short- and long-term complications.
Furthermore, although a considerable rate of improvement is obtained, not all patients
achieve remission. Hence, an appropriate selection of patients is essential to optimize
the outcomes.
The main objectives of the current study were to analyze the remission rates of T2DM
and to identify clinical factors predictive of this remission. The study involved a sample of
patients with T2DM and grade III–IV obesity undergoing bariatric surgery.
2. Materials and Methods
2.1. Study Design and Study Population
We designed a retrospective study to evaluate the possible factors involved in T2DM
remission at two years post-bariatric surgery. The patients were individuals who were
morbidly obese, had T2DM, and were undergoing bariatric surgery between January 2005
and December 2016. The study was approved by the Ethics Committee of our hospital
(ethical approval code number: TFG-15.19).
Inclusion criteria were the following: between 18 and 60 years of age, pre-operative
diagnosis of T2DM, BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 but with other associated
metabolic comorbidities. A follow-up of the patients was conducted for at least two years
post-surgery. Patients with pre-diabetes and T1DM were excluded.
2.2. Surgical Procedure
The election of surgical procedure was the responsibility of the surgeon, taking into
account the patient’s clinical and social characteristics. The two techniques performed were
gastric bypass (a technique involving a malabsorption element) and sleeve gastrectomy
(merely a restrictive intervention).
2.3. Evaluation of Variables Collected
The variables collated included the following: demographic data, anthropometric
measurements, duration of diabetes, anti-hyperglycemic medication, micro- and macro-
vascular complications, routine blood chemistry analyses (including FBG, HbA1c, total
cholesterol, triglycerides, LDL-cholesterol, and HDL-cholesterol), associated metabolic
comorbidities (including hypertension and dyslipidemia), and a bariatric procedure of
choice together with any early and late post-operative complications.
The diagnosis of T2DM was performed according to the following American Diabetic
Association (ADA) criteria: random plasma glucose ≥ 200 mg/dL (≥11.1 mmol/L) in pa-
tients with classic symptoms of hyperglycemia; fasting blood glucose (FBG) ≥ 126 mg/dL
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(≥6.99 mmol/L); or glycated hemoglobin (HbA1c) ≥ 6.5% [9]. Plasma glucose was deter-
mined in venous blood using the Modular DPD biochemistry system (Roche Diagnostics).
HbA1c was determined in a Cobas Integra 700 analyzer (Roche Diagnostics), using an
immunoturbidimetric method for anticoagulated venous whole blood. Diabetes remission
was defined as FBG < 126 mg/dL (<6.99 mmol/L) and HbA1c < 6.5% in the absence of
anti-hyperglycemic agents.
The chronic complications of diabetes were classified as follows: (a) macro-angiopathy—
including a history of coronary heart disease, cerebrovascular disease, and/or peripheral
arterial disease; (b) micro-angiopathy—including periodical evaluation and evidence of
retinopathy, albuminuria and renal function, and peripheral neuropathy. Retinography
was evaluated using a non-mydriatic TopCon camera. The urinary albumin excretion in
24-h urine or the spot urinary albumin-to-creatinine ratio was assessed and measured
using an immunoturbidometric assay in a Cobas Integra 700 analyzer (Roche Diagnostics).
The corresponding levels of albuminuria were defined as >30 mg/24 h or >30 mg/g,
respectively. A distal symmetric polyneuropathy assessment was performed with a 128-Hz
tuning fork and 10-g monofilament testing [10].
2.4. Statistical Analyses
Data were coded to ensure anonymity. Statistical analyses were performed using
the SPSS program (version 15.0 for Windows, GraphPad Software, San Diego, CA, USA).
Multivariate analyses were carried out using binary logistic regression models. The depen-
dent variable was the resolution of T2DM, while the independent variables were selected
based on clinical and statistical criteria of p < 0.05 in a bivariate analysis. Criteria for
inclusion and exclusion were 0.10 and 0.15 (PIN and POUT, respectively). Likewise, vari-
ables with values of p < 0.300 in a bivariate analysis were manually introduced to check if
the exclusion of any of these non-significant variables induced important changes in the
correlation coefficients of the other clinical variables in the model, pre-set at 20% (exponent
B, confounding variables).
3. Results
A total of 350 patients underwent bariatric surgery between January 2005 and Decem-
ber 2016, but only 94 were diagnosed with diabetes mellitus. Seven patients were excluded
because they had not been followed up for two years, and another four were excluded due
to a T1DM diagnosis. The patient-selection procedure is shown in Figure 1. Out of the
83 patients with T2DM included in the study, 45 (54.2%) underwent gastric bypass and
38 (45.8%) had sleeve gastrectomy. When analyzed according to the surgical technique
performed, a higher T2DM remission rate was observed in patients who underwent gastric
bypass versus sleeve gastrectomy (88.9% vs. 68.4%, respectively; p = 0.029).
Demographics, clinical characteristics, anthropometric measurements, and pre-operative
baseline biochemical values are shown in Tables 1 and 2. Two years post-surgery, the
percentage excess weight loss (%EWL) was 63.43 ± 18.59% and the percentage excess BMI
loss (%EBMIL) was 35.14 ± 10.49%. Hypertension, dyslipidemia, and T2DM remission
rates two years post-surgery were 65%, 70.2%, and 79.5%, respectively (p < 0.001).
Post-operative anthropometric measurements and the resolution of metabolic comorbidi-
ties are shown in Table 3. Apart from the post-operative complications caused by the surgery
itself, 15.66% of patients (n = 13) developed early complications (mainly surgical wound
infection), and 20.48% (n = 17) presented late complications (predominantly eventration).
Prior to conducting the bivariate analysis, the normality of distribution of quantitative
variables was evaluated with the Kolmogorov–Smirnov test. Subsequent analyses used
parametric or non-parametric tests. The bivariate analysis (Tables 4 and 5) showed that
patients with T2DM remission were younger (95%CI: 0.019–11.48, p = 0.041), had a higher
baseline BMI (95%CI: −5.18–10.61, p = 0.025), shorter duration of T2DM (p = 0.006), lower
HbA1c values (95%CI: 0.18–2.66, p = 0.047), and lower percentages of micro-angiopathy
(p < 0.001) and macro-angiopathy (p < 0.001). Fewer patients presented with a pre-operative
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insulin requirement (p < 0.001), a higher percentage excess weight loss (%EWL; 95%CI:
−25.91–−5.11, p = 0.004), and a percentage excess BMI loss (%EBMIL; 95%CI: −15.66–
−4.11, p = 0.001) post-surgery.




Figure 1. Patient-selection procedure and number of patients for each step of the process. A total of 
350 patients underwent bariatric surgery between January 2005 and December 2016; only 94 of the 
patients were diagnosed with diabetes mellitus. Seven patients were excluded because they had not 
been followed up for two years, and another four due to a T1DM diagnosis. Out of the 83 patients 
with T2DM included in the study, 45 underwent gastric bypass and 38 had sleeve gastrectomy. DM: 
diabetes mellitus; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus. 
Demographics, clinical characteristics, anthropometric measurements, and pre-
operative baseline biochemical values are shown in Tables 1 and 2. Two years post-
surgery, the percentage excess weight loss (%EWL) was 63.43 ± 18.59% and the percentage 
excess BMI loss (%EBMIL) was 35.14 ± 10.49%. Hypertension, dyslipidemia, and T2DM 
remission rates two years post-surgery were 65%, 70.2%, and 79.5%, respectively (p < 
0.001). 
Table 1. Pre-operative demographics, clinical characteristics, and anthropometric measurements in 
patients with T2DM who underwent bariatric surgery (n = 83). 
Variable Value 
Sex  
Female 1 51 (61.4%) 
Male 1 32 (38.6%) 
Age (years) 2 44.13 ± 10.38 
Baseline weight (kg) 2 139.71 ± 22.27 
Baseline BMI (kg/m2) 3 50.91 (46.48–54.01) 
T2DM duration (years) 3 5.01 (3.01–15.50) 
<5 years 1 36 (48.6%) 
5–10 years 1 13 (17.6%) 
11–20 years 1 20 (27%) 
>20 years 1 5 (6.8%) 
Complications of diabetes  
Micro-angiopathy 1 16 (23.2%) 
Macro-angiopathy 1 7 (10.3%) 
Diabetes medication  
Non-insulin treatment 1 61 (77.2%) 
Insulin treatment 1 5 (6.3%) 
Combination treatment 1 13 (16.5%) 
Active tobacco habit 1 24 (29.3%) 
Hypertension 1 60 (72.3%) 
Dyslipidemia 1 57 (68.7%) 
Figure 1. Patient-selection procedure and number of patients for each step of the process. A total of 350 patients underwent
bariatric surgery between January 2005 and December 2016; only 94 of the patients were diagnosed with diabetes mellitus.
Seven patien s were xcluded b cause they had not been followed up for two years, and nother four due to a T1DM
diagnosis. Out f the 83 patients with T2DM i cluded in the s udy, 45 un erwent gastric bypass and 38 had sleeve
gastrectomy. DM: diabetes mellitus; T1DM: type 1 iabetes mellitus; T2DM: type 2 diabetes mellitus.
Table 1. Pre-operative demographics, clinical characteristics, and anthropometric measurements in
patients with T2DM who underwent bariatric surgery (n = 83).
Variable Value
Sex
Female 1 51 (61.4%)
Male 1 32 (38.6%)
Age (years) 2 44.13 ± 10.38
Baseline weight (kg) 2 139.71 ± 22.27
Baseline BMI (kg/m2) 3 50.91 (46.48–54.01)
T2DM duration (years) 3 5.01 (3.01–15.50)
<5 years 1 36 (48.6%)
5–10 years 1 13 (17.6%)
11–20 years 1 20 (27%)
>20 years 1 5 (6.8%)
Complications of diabetes
Micro-angiopathy 1 16 (23.2%)
Macro-angiopathy 1 7 (10.3%)
Diabetes medication
Non-insulin treatment 1 61 (77.2%)
Insulin treatment 1 5 (6.3%)
Combination treatment 1 13 (16.5%)
Active tobacco habit 1 24 (29.3%)
Hypertension 1 60 (72.3%)
Dyslipidemia 1 57 (68.7%)
BMI = body mass index; T2DM = type 2 diabetes mellitus. 1 Data expressed as n (%). 2 Data expressed
as mean ± standard deviation. 3 Data expressed as median (interquartile range).
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Table 2. Pre-operative biochemical values of patients with T2DM who underwent bariatric surgery
(n = 83).
Variable Value
Total cholesterol (mmol/L) 1 5.16 ± 1.12
Triglycerides (mmol/L) 2 1.91 (1.42–2.86)
LDL–cholesterol (mmol/L) 2 3.27 (2.57–4.09)
HDL–cholesterol (mmol/L) 1 1.07 ± 0.28
Fasting blood glucose (mmol/L) 2 7.27 (6.05–9.16)
HbA1c (mmol/L) 1 9.1 ± 2.2
LDL = low-density lipoprotein; HDL = high-density lipoprotein; HbA1c = glycated hemoglobin. 1 Data expressed
as mean ± standard deviation. 2 Data expressed as median (interquartile range).
Table 3. Post-operative anthropometric measurements and resolution of metabolic comorbidities.
Variable Baseline Two Years Post-Surgery
Weight (kg) 1 139.71 ± 22.27 90.31 ± 17.47
BMI (kg/m2) 2 50.91 (46.48–54.01) 33.09 ± 6.31
%EWL (%) 1 – 63.43 ± 18.59
%EBMIL (%) 1 – 35.14 ± 10.49
T2DM 3 83 (100) 17 (20.5)
Hypertension 3 60 (72.73) 21 (25.9)
Dyslipidemia 3 57 (68.7) 17 (21.0)
BMI = body mass index; %EWL = percentage excess weight loss; %EBMIL = percentage excess BMI loss;
T2DM = type 2 diabetes mellitus. 1 Data expressed as mean ± standard deviation. 2 Data expressed as median
(interquartile range). 3 Data expressed as n (%).
Table 4. Bivariate analysis of factors predictive of T2DM remission.
Predictive Factor T2DM Remission (n = 66) T2DM Persistence (n = 17) p Value 95% CI
Sex
Female 1 27 (40.9) 5 (29.4)
0.420 –Male 1 39 (59.1) 12 (70.5)
Age (years) 2 42.95 ± 10.16 48.10 ± 9.72 0.041 0.019–11.48
T2DM duration
<5 years 1 34 (51.5) 2 (11.7)
0.006 –≥5 years 1 24 (36.4) 14 (82.3)
Bariatric surgery procedure
Gastric bypass 1 40 (60.6) 5 (29.4)
0.029 –Sleeve gastrectomy 1 26 (39.4) 12 (70.5)
Hypertension
Yes 1 47 (71.2) 13 (76.4)
0.769 –No 1 19 (28.7) 4 (17.4)
Dyslipidemia
Yes 1 42 (63.6) 15 (88.3)
0.077 –No 1 24 (36.3) 2 (11.7)
Active tobacco habit
Yes 1 19 (28.7) 5 (29.4)
0.917 –No 1 47 (71.2) 11 (64.7)
Micro-angiopathy
Yes 1 3 (4.5) 13 (76.4)
<0.001 –No 1 50 (75.7) 3 (17.4)
Macro-angiopathy
Yes 1 1 (1.51) 6 (35.3)
<0.001 –No 1 52 (78.7) 9 (52.9)
Diabetes medication
Non-insulin treatment 1 56 (75.7) 5 (29.4)
<0.001 –Insulin treatment 1 1 (1.5) 4 (23.5)
Combination treatment 1 5 (7.5) 8 (47.1)
T2DM = type 2 diabetes mellitus; CI = confidence interval. 1 Data expressed as n (%). 2 Data expressed as mean ± standard deviation.
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After adjusting for statistically significant variables highlighted in the bivariate analy-
sis, as well as for clinically relevant variables (age, sex, bariatric surgery procedure, T2DM
duration, BMI, presence of surgical complications, and anti-hyperglycemic medication), the
multivariate analysis confirmed that a higher preoperative BMI (OR 1.886; 95%CI: 1.09–3.24;
p = 0.022) and the absence of macro-angiopathy complications at the time of surgery (OR
34.667; 95%CI: 3.720–323.08; p = 0.002) were significantly associated with T2DM remis-
sion. Additionally, the clinical evolution of T2DM over the five years (OR 0.022; 95%CI:
0.001–0.846; p = 0.004) and the pre-surgery insulin treatment—in monotherapy (OR: 0.001;
95%CI: 0.001–0.158; p = 0.009) or in combination with other anti-hyperglycemic drugs (OR:
0.001; 95%CI: 0.001–0.125; p = 0.014)—were associated with lower odds of T2DM remission
(Table 6). With respect to the surgical technique, a statistically significant difference in
the remission variable was observed using a bivariate analysis. However, in multivariate
analyses (after adjusting for the variables of age, sex, bariatric surgery procedure, T2DM
duration, BMI, presence of surgical complications, and anti-hyperglycemic medication),
the bariatric procedure did not appear as a predictor of T2DM remission.
Table 5. Bivariate analysis of biochemical values and anthropometric measurements.
Predictive Factor T2DM Remission (n = 66) T2DM Persistence (n = 17) p Value 95%CI
Fasting blood glucose (mmol/L) 1 7.13 (5.94–8.69) 8.49 (6.44–10.32) 0.117 −14.74–46.35
HbA1c (mmol/L) 2 10.0 ± 2.1 11.0 ± 2.2 0.047 0.18–2.66
Total cholesterol (mmol/L) 2 5.21 ± 1.08 4.91 ± 1.32 0.395 −38.88–15.53
Triglycerides (mmol/L) 1 1.83 (1.36–2.84) 2.37 (1.66–3.29) 0.187 −38.01–92.91
LDL–cholesterol (mmol/L) 1 3.27 (2.58–3.98) 3.26 (1.9–9.99) 0.901 −246.9–512.8
HDL–cholesterol (mmol/L) 2 1.06 ±0.25 1.16 ± 0.51 0.685 −17.28–24.35
Baseline weight (kg) 2 142.67 ± 19.83 125.30 ± 26.16 0.046 −29.39–0.41
Baseline BMI (kg/m2) 2 51.70 ± 7.88 47.79 ± 6.74 0.025 −5.18–10.6
%EWL (%) 2 66.17 ± 16.80 50.66 ± 21.67 0.004 −25.91–−5.11
%EBMIL (%) 2 36.89 ± 9.76 27.01 ± 10.24 0.001 −15.66–−4.11
T2DM = Type 2 diabetes mellitus; HbA1c = glycated hemoglobin; LDL = low-density lipoprotein; HDL = high-density lipoprotein;
BMI = Body mass index; %EWL = percentage excess weight loss; %EBMIL = percentage excess BMI loss; CI = confidence interval. 1 Data
expressed as median (interquartile range). 2 Data expressed as mean ± standard deviation.
Table 6. Multivariable logistic regression analysis for factors predictive of T2DM remission.
Predictive Factor Exp (B) (95%CI) p Value
BMI baseline 1.886 (1.09–3.24) 0.022
Female sex 0.018 (0.01–1.79) 0.087
Duration of diabetes
<5 years 3.997 (0.104–158.8) 0.456
≥5 years 0.022 (0.001–0.846) 0.040
Diabetes medication
Insulin treatment 0.001 (0.001–0.158) 0.009
Combination treatment 0.001 (0.001–0.125) 0.014
Absence of macro-angiopathy 34.67 (3.72–323.08) 0.002
BMI = Body mass index; CI = confidence interval. Adjusted for the confounding variables of age, sex, bariatric surgery
technique, T2DM duration, BMI, anti-hyperglycemic medication, and presence of T2DM chronic complications.
4. Discussion
Achieving optimal glycemic control (defined as HbA1c < 7%) in patients with T2DM
and poor metabolic control continues to be difficult despite rigorous medical treatment [11].
However, recent randomized controlled trials have provided evidence of greater efficacy of
T2DM remission following bariatric surgery as compared to standard or intensive medical
therapy [12,13]. As such, metabolic surgery could be considered a therapeutic alternative
in patients with T2DM and a BMI lower than that currently accepted. Clinical practice
guidelines do not recommend metabolic surgery routinely in patients with T2DM and a
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BMI between 30 and 35 kg/m2, considering there is not enough data on the long-term
reduction of cardiovascular disease morbidity and mortality, nor on the beneficial effects on
micro-vascular complications [14]. In our hospital, gastric bypass is effective in resolving
metabolic comorbidities associated with obesity, and has achieved good resolution rates
of hypertension, dyslipidemia, and T2DM of 71.93%, 91.38%, and 82.93%, respectively
(p < 0.001) [15].
Although the physio-pathological mechanisms underlying the metabolic effects of
bariatric surgery are complex (and continue to receive research attention), T2DM remission
appears to be related to an absence of the anti-incretin effect, which is attributed to a
proximal jejunum exclusion and a lower oxidation of free fatty acids, changes in gut flora,
together with an early and elevated post-prandial secretion of GLP1 that occurs a few weeks
post-bariatric surgery [16,17]. Recently, another important benefit of sleeve gastrectomy
has been reported, i.e., a post-surgery normalization of free radicals, with values decreased
to levels comparable to those of control individuals [18]. Furthermore, some authors
consider bariatric surgery as an epigenetic factor influencing the anatomic and physiologic
modifications induced in gene expression by these surgical techniques [19].
Our study sought to identify the factors predictive of T2DM following bariatric surgery,
so as to enable the selection of patients for the surgical procedure.
Appropriate patient selection is an important determinant of the success of bariatric
surgery. It is important to know the pre-operative characteristic of the patient so as to
achieve a better therapeutic response, i.e., the best outcome for the particular patient, and
with a better cost-effectiveness for the institution. In our study, patients with a higher BMI,
a shorter duration of clinical evolution, who are not on insulin therapy, and who had no
evidence of macro- or micro-vascular complications, were more likely to have a resolution
of their type 2 diabetes. The benefit to the pancreatic islet that occurs post-bariatric surgery
probably depends on the beta-cell mass of the subject at the time of the intervention.
Hence, if confirmed in prospective studies with larger sample sizes, a delay in selecting
patients with T2DM and obesity would be avoided when considering bariatric surgery.
The influence of baseline BMI on T2DM remission is debated. Some authors confirm BMI
as a predictive factor in remission, while others see it as having a neutral effect [20–23]. In
our study, a higher baseline (pre-operative) BMI was associated with a higher remission
rate. We evaluated whether this could be influenced by the type of surgical technique
employed; the rationale being that sleeve gastrectomy is frequently used in clinical practice
in subjects with a lower BMI. This is also associated with lower remission rates of T2DM
as compared to gastric bypass, albeit these differences do not reach statistical significance
in our study. In our literature search, we were unable to identify significant relationships
between pre-operative BMI and diabetes remission. Some authors have described a positive
relationship between pre-operative BMI and the degree of post-surgery weight loss [24].
Other studies also show that T2DM remission is associated with weight loss post-bariatric
surgery [25]. Weight loss implies a greater decrease in inflammation parameters and in
insulin resistance [18]. All these data suggest that patients with a higher BMI present
greater weight loss and a decrease in insulin resistance. However, randomized clinical
trials with long-term clinical follow-ups are necessary to confirm these findings.
The duration of T2DM is one of the most analyzed predictive factors in diabetes litera-
ture. In our study, a T2DM duration of > 5 years was associated with an absence of remission
of T2DM. Different thresholds have been proposed (between 5 and 10 years), beyond which
the probability of achieving T2DM remission decreases significantly. Leoneti et al. de-
scribed T2DM resolution rates close to 100% in patients with a T2DM duration of <10 years
and who are undergoing sleeve gastrectomy, whereas a remission of 40% was identified
in patients with a T2DM duration of >10 years [26]. Patients with a longer T2DM du-
ration have a greater reduction in beta cell functionality. Hence, although they benefit
from a reduction in insulin resistance post-surgery, they do not achieve complete T2DM
remission [27]. Some authors have proposed baseline serum C-peptide as an indicator
of pancreatic beta cell mass and insulin secretion, which may consequently be related to
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T2DM remission [28]. However, clinical relevance of C-peptide has not been well studied
in diabetic literature, and cut-off points have not been clearly established.
Similarly, pre-operative insulin treatment, in monotherapy or combined with other
anti-hyperglycemic medication, suggests a high level of pancreatic beta cell dysfunction
that may not respond effectively to incretin secretion post-bariatric surgery [29]. This
would indicate that pre-surgery insulin therapy is associated with significantly lower re-
mission rates as compared to patients undergoing treatment with non-insulin anti-diabetic
drugs [30,31]. In our study, the pre-operative insulin requirement, in monotherapy or com-
bined with other hypoglycemic agents, was associated with an absence of T2DM remission.
In the review by Tsilingiris et al., age and sex are highlighted as factors with a neutral
effect on T2DM remission in the majority of published studies [32]. Some of the authors
cited in this meta-analysis detected an association between higher age and the absence
of diabetes remission. This is presumably due to a greater grade of pancreatic beta cell
dysfunction and, as such, with T2DM progression [28,33]. In our present study, none of
these variables was identified as a factor predictive of T2DM remission.
There is a paucity of data assessing the presence/absence of macro- and micro-
angiopathy in relation to T2DM remission. In our study, we found a strong association
between the absence of macro-angiopathy and T2DM remission; an aspect that certainly
warrants further investigation.
It is worth noting that our study also describes the high-resolution rates of hy-
pertension and dyslipidemia post-bariatric surgery, similar to those described in the
Buchwald et al. meta-analysis [7]. Tham et al. correlated this effect with metabolic co-
morbidities and observed a significant reduction in cardiovascular disease risk [34]. In
a long-term follow-up, the SOS study demonstrated a significant decrease in mortality
from cardiovascular disease in patients who underwent bariatric surgical treatment, as
compared to those who were receiving medical treatment [35].
With respect to the safety of the surgical procedures, our late complication rates
are similar to those described by other authors [34]. Additionally, as in other studies,
a lower incidence of complications was observed in patients undergoing laparoscopic
surgery [30,36].
It would be of considerable interest to establish parameters that would influence the
clinical guidelines for bariatric surgery. These include the following: (1) ideal timelines post-
metabolic surgery to evaluate the resolution of T2DM; (2) the most appropriate surgical
technique option (assessing risks and benefits); (3) the BMI cut-off value for surgical
intervention; and (4) new pharmacological agents for T2DM treatment with proven effects
on cardiovascular disease risk. Randomized studies with a long-term follow-up would be
necessary to evaluate these questions.
The main strengths of our study are as follows: (1) the study was conducted in a
real clinical practice setting, which included all patients with T2DM and obesity referred
to our hospital over a period of more than 10 years; (2) the identification of factors have
direct clinical applicability since the data could predict a better response to surgery, and
consequently allow for more efficient patient selection. However, our study also has some
limitations. Although the study included all the patients with T2DM and obesity treated
in our center over a period of 10 years, the sample size remains relatively small (albeit
comparable to other similar published studies). Nevertheless, we observed statistically
significant and clinically relevant associations. The retrospective nature of the study
and two years of follow-up may not be sufficient to derive definitive conclusions in the
surgical treatment of T2DM because it is not known whether patients will experience
T2DM recurrence in the long-term. Finally, this study was conducted in a single center; the
drawback being that the results may not be generalizable to patients with different social
and clinical characteristics.
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5. Conclusions
Bariatric surgery is a safe and effective technique for sustained weight loss in the
short-to-medium term. Patients with T2DM and obesity grade II (or higher) experienced
an elevated remission rate of diabetes in the two-year post-bariatric surgery follow-up.
A higher baseline BMI, a shorter duration of the T2DM, non-insulin treatment, and the
absence of macro-vascular complications are factors predictive of T2DM remission post-
surgery. Prospective studies with larger sample sizes are required to confirm the signif-
icance of clinical factors predictive of T2DM remission following bariatric surgery. The
current study provides an insight into post-surgery alterations and suggests guidelines for
patient selection for metabolic surgery.
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